Camber Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Camber Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000,000	Closed	-$35M	–	41
2021 Q4	$35M	Sell	3,000,000 -2,500,000	-45%	-$30.7M	1.2%	26
2021 Q3	$71.8M	Sell	5,500,000 -2,000,000	-27%	-$25.8M	2.21%	23
2021 Q2	$96.5M	Hold	7,500,000	–	–	3.25%	14
2021 Q1	$83.8M	Hold	7,500,000	–	–	2.88%	13
2020 Q4	$85.4M	Buy	7,500,000 +250,000	+3%	+$2.74M	3%	16
2020 Q3	$65.2M	Buy	7,250,000 +750,000	+12%	+$7.45M	3.44%	9
2020 Q2	$67.1M	Buy	+6,500,000	New	+$66.5M	3.84%	10

Other funds holding IRWD

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Camber Capital Management's IRWD Position: Q1 2022 in Review

Camber Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2022, closing a stake of 3,000,000 shares — an estimated $35M sold.

Camber Capital Management first reported a position in IRWD in Q2 2020 and held it in 7 quarters. The position peaked at $96.5M in Q2 2021. 221 funds tracked by Wall St. Rank hold IRWD as of Q1 2022.

Camber Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Camber Capital Management sold 3,000,000 Ironwood Pharmaceuticals shares in Q1 2022, an estimated $35M.
Camber Capital Management first reported a position in Ironwood Pharmaceuticals in Q2 2020 and held it in 7 quarters.
Camber Capital Management's Ironwood Pharmaceuticals position peaked at $96.5M in Q2 2021.
221 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2022.

Based on Camber Capital Management's 13F filing for Q1 2022, filed 16 May 2022.